Coinciding with last month's annual meeting of the American Society of Clinical Oncology, at least one business launched with a plan to use genetic information from patient tumors to help guide treatment. Michael Eisenstein investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roychowdhury, S. et al. Sci. Transl. Med. 3, 111ra121 (2011).
Palmer, G.A. et al. Abstract no. 10590 presented at the American Society for Clinical Oncology Meeting, June 1–5, 2012 http://abstract.asco.org/AbstView_114_99137.html
Gerlinger, M. et al. N. Engl. J. Med. 366, 883–892 (2012).
Poste, G. Nature 469, 156–157 (2011).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Reading cancer's blueprint. Nat Biotechnol 30, 581–584 (2012). https://doi.org/10.1038/nbt.2292
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2292
